National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials
that Promote Tissue Repair
August 14, 2007: 06:00 AM EST
MOUNTAINSIDE, N.J., Aug. 14 /PRNewswire-
Cell Holding, Inc. , today announced that Michael Cohen, CEO of the
Company, and Jacob Cohen, have discovered biomaterial derived from
non- embryonic stem cells, which appears to promote tissue repair in
various wound care applications.
On July 26, 2007, the Company announced that while using its
proprietary embryonic stem cell lines, Michael and Jacob Cohen
discovered a group of biomaterials that in preclinical studies appear
to increase the rate at which the tissue surrounding a wound heals,
and ultimately, the strength of such newly formed tissue. Today, the
Company reports that Michael and Jacob Cohen have also been able to
derive such tissue repair promoting biomaterials from non-embryonic
stem cells, such as umbilical cord blood cells.
The Company has filed provisional patent applications with the United
States Patent and Trademark Office, which cover both the July 26,
2007 discovery and the discovery announced today.
According to Michael Cohen "By deriving these novel biomaterials from
non- embryonic stem cells, such as umbilical cord blood, we believe
we can avoid the costly and time consuming procedures that plague
therapies developed from embryonic stem cells. This new discovery
gives us the ability to cultivate tissue repair and wound healing
products and commence clinical trials of such products in an
expedited manner."
National Stem Cell Holding, Inc. is a biotechnology company focused
on developing therapeutics based upon the use of human cells and
their derivatives. The Company is developing a pipeline of
proprietary stem cell therapeutics, with a particular focus on
finding a cure for diabetes. In addition to its work with stem cell
therapeutics, the Company is working to leverage the commercial
infrastructure and product development capabilities of its wholly-
owned subsidiary, The Sperm Bank of NY. The Company's investigational
products are focused on the improvement of the quality of life for
patients and their families. National Stem Cell Holding, Inc. is
headquartered in Mountainside, NJ.
Except for the historical information contained herein, the matters
set forth in this press release are forward-looking statements within
the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. Words such as "expect
(s)," "feel(s)," "believe(s),
similar expressions are intended to identify forward-looking
statements, which include, but are not limited to statements
regarding: the ability of the Company to perform clinical trials, the
ability of the biomaterials to promote tissue repair and the variety
of wound care applications. All of such forward-looking statements
are not guarantees of future performance. They are based on
management's current expectations and are subject to risks and
uncertainties that are difficult to predict and generally beyond the
control of the Company, and that could cause actual results to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and
uncertainties include, but are not limited to: the risk that the
patent applications will not be granted, the risk that the analysis
of future data will not warrant continuation of development; the risk
that the FDA, the institutional review boards for the clinical sites
or the investigators may not agree with the Company's assessment of
the results and may not permit future trials; the risk that concerns
may arise from additional analysis or data; and the risk that the
Company may encounter other unexpected hurdles. Readers are cautioned
not to place undue reliance on these forward-looking statements that
speak only as of the date hereof. National Stem Cell Holding, Inc.
does not undertake any obligation to update or revise any forward-
looking statements, to reflect changes to management's expectations,
change in events, conditions or circumstances after the date hereof,
or the occurrence of or non-occurrence of any events, new information
or otherwise.
http://money.
7-1.htm
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
